CN102596189A - 抑制粘蛋白分泌的方法 - Google Patents
抑制粘蛋白分泌的方法 Download PDFInfo
- Publication number
- CN102596189A CN102596189A CN2010800492171A CN201080049217A CN102596189A CN 102596189 A CN102596189 A CN 102596189A CN 2010800492171 A CN2010800492171 A CN 2010800492171A CN 201080049217 A CN201080049217 A CN 201080049217A CN 102596189 A CN102596189 A CN 102596189A
- Authority
- CN
- China
- Prior art keywords
- compositions
- guaifenesin
- effective dose
- disease
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HSRJKNPTNIJEKV-UHFFFAOYSA-N Guaifenesin Chemical compound COC1=CC=CC=C1OCC(O)CO HSRJKNPTNIJEKV-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 229960002146 guaifenesin Drugs 0.000 title claims abstract description 66
- 230000028327 secretion Effects 0.000 title claims abstract description 32
- 108010063954 Mucins Proteins 0.000 title claims description 19
- 102000015728 Mucins Human genes 0.000 title claims description 19
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 37
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 8
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 5
- 239000003434 antitussive agent Substances 0.000 claims description 5
- 229940124584 antitussives Drugs 0.000 claims description 5
- 239000000850 decongestant Substances 0.000 claims description 5
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- YQSHYGCCYVPRDI-UHFFFAOYSA-N (4-propan-2-ylphenyl)methanamine Chemical compound CC(C)C1=CC=C(CN)C=C1 YQSHYGCCYVPRDI-UHFFFAOYSA-N 0.000 claims description 3
- PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 claims description 3
- WFXURHIXPXVPGM-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 WFXURHIXPXVPGM-UHFFFAOYSA-N 0.000 claims description 3
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 3
- KBAUFVUYFNWQFM-UHFFFAOYSA-N Doxylamine succinate Chemical compound OC(=O)CCC(O)=O.C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 KBAUFVUYFNWQFM-UHFFFAOYSA-N 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 3
- SRGKFVAASLQVBO-BTJKTKAUSA-N brompheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 SRGKFVAASLQVBO-BTJKTKAUSA-N 0.000 claims description 3
- 229960003108 brompheniramine maleate Drugs 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229960003291 chlorphenamine Drugs 0.000 claims description 3
- 229960004106 citric acid Drugs 0.000 claims description 3
- 229960002689 clemastine fumarate Drugs 0.000 claims description 3
- 229960003782 dextromethorphan hydrobromide Drugs 0.000 claims description 3
- 229960005008 doxylamine succinate Drugs 0.000 claims description 3
- 229960002179 ephedrine Drugs 0.000 claims description 3
- 230000003203 everyday effect Effects 0.000 claims description 3
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims description 3
- 229960003592 fexofenadine Drugs 0.000 claims description 3
- 230000002045 lasting effect Effects 0.000 claims description 3
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims description 3
- 229960000582 mepyramine Drugs 0.000 claims description 3
- 229960003956 phenindamine tartrate Drugs 0.000 claims description 3
- 229960003733 phenylephrine hydrochloride Drugs 0.000 claims description 3
- OCYSGIYOVXAGKQ-FVGYRXGTSA-N phenylephrine hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=CC(O)=C1 OCYSGIYOVXAGKQ-FVGYRXGTSA-N 0.000 claims description 3
- IZRPKIZLIFYYKR-UHFFFAOYSA-N phenyltoloxamine Chemical compound CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 IZRPKIZLIFYYKR-UHFFFAOYSA-N 0.000 claims description 3
- 229960001526 phenyltoloxamine Drugs 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229960003910 promethazine Drugs 0.000 claims description 3
- 229960003447 pseudoephedrine hydrochloride Drugs 0.000 claims description 3
- BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 claims description 3
- 238000011284 combination treatment Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims 1
- 210000003097 mucus Anatomy 0.000 abstract description 18
- 210000004027 cell Anatomy 0.000 description 16
- 230000000420 mucociliary effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 5
- 239000003172 expectorant agent Substances 0.000 description 5
- 230000003419 expectorant effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102100022496 Mucin-5AC Human genes 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000518 rheometry Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 210000004081 cilia Anatomy 0.000 description 2
- 230000001886 ciliary effect Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004146 energy storage Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- MXRIRQGCELJRSN-UHFFFAOYSA-N O.O.O.[Al] Chemical compound O.O.O.[Al] MXRIRQGCELJRSN-UHFFFAOYSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000004878 submucosal gland Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/558,517 US20110065744A1 (en) | 2009-09-12 | 2009-09-12 | Method Of Inhibiting Mucin Secretion |
| US12/558,517 | 2009-09-12 | ||
| GB1002039.4 | 2010-02-09 | ||
| GBGB1002039.4A GB201002039D0 (en) | 2010-02-09 | 2010-02-09 | Method of inhibiting mucin secretion |
| PCT/GB2010/051525 WO2011030163A1 (en) | 2009-09-12 | 2010-09-13 | Use of guaifenesin for inhibiting mucin secretion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102596189A true CN102596189A (zh) | 2012-07-18 |
Family
ID=42941393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010800492171A Pending CN102596189A (zh) | 2009-09-12 | 2010-09-13 | 抑制粘蛋白分泌的方法 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2475360A1 (enExample) |
| JP (1) | JP2013504554A (enExample) |
| KR (1) | KR20120068889A (enExample) |
| CN (1) | CN102596189A (enExample) |
| AU (1) | AU2010294008B2 (enExample) |
| BR (1) | BR112012005517A2 (enExample) |
| CA (1) | CA2773611A1 (enExample) |
| MX (1) | MX2012003042A (enExample) |
| MY (1) | MY161187A (enExample) |
| RU (1) | RU2012114323A (enExample) |
| WO (1) | WO2011030163A1 (enExample) |
| ZA (1) | ZA201201822B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1206995A1 (en) * | 2012-04-06 | 2016-01-22 | The Uab Research Foundation | Methods for increasing cftr activity |
| KR102211605B1 (ko) * | 2018-02-26 | 2021-02-04 | 대한민국 | 개구리 배아를 이용한 기도 뮤신 분비 억제제의 스크리닝 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA963590B (en) * | 1995-05-10 | 1996-11-19 | Adcock Ingram Ltd | Pharmaceutical composition |
| US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
| US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
| EP1471872A2 (en) * | 2002-02-04 | 2004-11-03 | Pharmacia Corporation | Treatment of colds and cough with a combination of a cyclooxygenase-2 selective inhibitor and a colds and cough active ingredient and compositions thereof |
| CN1835942A (zh) * | 2003-06-19 | 2006-09-20 | 金纳莱公司 | 粘蛋白合成抑制剂 |
| US20050095288A1 (en) * | 2003-11-03 | 2005-05-05 | Andrx Labs, Llc | Decongestant and expectorant tablets |
| US20050266032A1 (en) * | 2003-12-17 | 2005-12-01 | Sovereign Pharmaceuticals, Ltd. | Dosage form containing multiple drugs |
| US20080014261A1 (en) * | 2006-07-12 | 2008-01-17 | Giordano John A | Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction |
| US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
-
2010
- 2010-09-13 BR BR112012005517A patent/BR112012005517A2/pt not_active Application Discontinuation
- 2010-09-13 MY MYPI2012001112A patent/MY161187A/en unknown
- 2010-09-13 CA CA2773611A patent/CA2773611A1/en not_active Abandoned
- 2010-09-13 AU AU2010294008A patent/AU2010294008B2/en not_active Ceased
- 2010-09-13 CN CN2010800492171A patent/CN102596189A/zh active Pending
- 2010-09-13 WO PCT/GB2010/051525 patent/WO2011030163A1/en not_active Ceased
- 2010-09-13 MX MX2012003042A patent/MX2012003042A/es unknown
- 2010-09-13 RU RU2012114323/15A patent/RU2012114323A/ru unknown
- 2010-09-13 EP EP10757117A patent/EP2475360A1/en not_active Ceased
- 2010-09-13 KR KR1020127007996A patent/KR20120068889A/ko not_active Withdrawn
- 2010-09-13 JP JP2012528455A patent/JP2013504554A/ja active Pending
-
2012
- 2012-03-13 ZA ZA2012/01822A patent/ZA201201822B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| 徐怀诚: "愈创木酚甘油醚对HIV感染病人鼻和鼻窦炎的治疗作用", 《国际耳鼻咽喉头颈外科杂志》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011030163A1 (en) | 2011-03-17 |
| ZA201201822B (en) | 2013-05-29 |
| AU2010294008B2 (en) | 2014-08-14 |
| MY161187A (en) | 2017-04-14 |
| BR112012005517A2 (pt) | 2016-04-19 |
| CA2773611A1 (en) | 2011-03-17 |
| MX2012003042A (es) | 2012-05-29 |
| KR20120068889A (ko) | 2012-06-27 |
| AU2010294008A1 (en) | 2012-04-05 |
| EP2475360A1 (en) | 2012-07-18 |
| JP2013504554A (ja) | 2013-02-07 |
| RU2012114323A (ru) | 2013-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ammit et al. | Mast cell numbers are increased in the smooth muscle of human sensitized isolated bronchi. | |
| Wheatley et al. | Rapid evolution and host immunity drive the rise and fall of carbapenem resistance during an acute Pseudomonas aeruginosa infection | |
| Tomaki et al. | Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis | |
| Bush et al. | Mucus properties in children with primary ciliary dyskinesia: comparison with cystic fibrosis | |
| Kiio et al. | Nano-scientific application of atomic force microscopy in pathology: from molecules to tissues | |
| JP2016006088A (ja) | ファブリー病に対する治療の選択を診断し、評価するためのアッセイ | |
| Willis et al. | The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus | |
| TWI635180B (zh) | 評估口腔健康的方法 | |
| Makkar et al. | Alcohol consumption, hepatic iron load and the risk of amoebic liver abscess: a case-control study | |
| Lo Bello et al. | Role of the mucins in pathogenesis of COPD: implications for therapy | |
| Danes et al. | Oyster ciliary inhibition by cystic fibrosis culture medium | |
| CN102596189A (zh) | 抑制粘蛋白分泌的方法 | |
| Zeng et al. | Amygdalin delays cartilage endplate degeneration and improves intervertebral disc degeneration by inhibiting NF-κB signaling pathway and inflammatory response | |
| CN117815292A (zh) | 一种缓解高尿酸血症的复合益生菌后生元发酵物及其应用 | |
| He et al. | NanoSIMS imaging reveals unexpected heterogeneity in nutrient uptake by brown adipocytes | |
| JPH08502978A (ja) | 呼吸器病治療の査定用コンパクション検定 | |
| Geerts et al. | Cobblestone HUVECs: a human model system for studying primary ciliogenesis | |
| JP2023510232A (ja) | ロドコッカス・ルーバーの細胞壁骨格の再生医学における用途 | |
| Buchwald | Abnormal levels of 3': 5'-cyclic AMP in isoproterenol-stimulated fibroblasts from patients with cystic fibrosis. | |
| Schroder et al. | Skeletal muscle-specific calpastatin overexpression mitigates muscle weakness in aging and extends life span | |
| US20110065744A1 (en) | Method Of Inhibiting Mucin Secretion | |
| Duncan et al. | In Vivo Characterization of Intracortical Probes with Focused Ion Beam-Etched Nanopatterned Topographies | |
| Hagen et al. | Giardia's domed ventral disc architecture is essential for attachment and contributes to epithelial barrier disruption | |
| Dijkman et al. | Antileukoprotease in sputum during bronchial infections | |
| Ziegler et al. | Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann–Pick disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120718 |
|
| RJ01 | Rejection of invention patent application after publication |